(2-Amino-4-{3-[5-amino-4-((S)-2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methoxy-phenoxy]-propoxy}-5-methoxy-phenyl)-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-methanone | 260391-65-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-Amino-4-{3-[5-amino-4-((S)-2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methoxy-phenoxy]-propoxy}-5-methoxy-phenyl)-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-methanone
• CAS: 260391-65-9
• 化学式: C₂₉H₄₀N₄O₈
• 分子量: 572.659
• InChiKey: LYLPDUGTCAPGOB-OALUTQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  41.0
• 可旋转键数：
  12.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  170.04
• 氢给体数：
  4.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  (2-Amino-4-{3-[5-amino-4-((S)-2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methoxy-phenoxy]-propoxy}-5-methoxy-phenyl)-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-methanone 在 吡啶 、 N-甲基吲哚酮 、 四丙基高钌酸铵 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 (4-nitrophenyl)methyl (6S,6aS)-3-[3-[[(6S,6aS)-6-hydroxy-2-methoxy-5-[(4-nitrophenyl)methoxycarbonyl]-11-oxo-6a,7,8,9-tetrahydro-6H-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-6-hydroxy-2-methoxy-11-oxo-6a,7,8,9-tetrahydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carboxylate
  参考文献：
  名称：

  Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT

  摘要：

  Three N10-(4-nitrobenzyl)carbamate-protected PBD prodrugs (9a, 9b and 15) have been synthesized and evaluated for potential use in nitroreductase-based ADEPT and GDEPT therapies. An approximately 100-fold activation was observed for the DC-81 prodrug 9a. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00404-2
• 作为产物：
  描述：

  ((propane-1,3-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methanone) 在 镍 、 肼 作用下， 以 甲醇 为溶剂， 以70%的产率得到(2-Amino-4-{3-[5-amino-4-((S)-2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methoxy-phenoxy]-propoxy}-5-methoxy-phenyl)-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-methanone
  参考文献：
  名称：

  Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT

  摘要：

  Three N10-(4-nitrobenzyl)carbamate-protected PBD prodrugs (9a, 9b and 15) have been synthesized and evaluated for potential use in nitroreductase-based ADEPT and GDEPT therapies. An approximately 100-fold activation was observed for the DC-81 prodrug 9a. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00404-2